http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102292321-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-416 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-56 |
| filingDate | 2009-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102292321-B |
| titleOfInvention | The carbonic acid derivatives of the pyrazolyl replacement of this receptor associated conditions is used for the treatment of as prostacyclin (PGI2) receptor modulators |
| abstract | The present invention relates to pyrazole derivatives and the pharmaceutical composition thereof of the formula Ia regulating PGI2 receptor active.The compounds of this invention and pharmaceutical composition thereof relate to the method for the effectively following illness for the treatment of: arterialness pulmonary hypertension (PAH) and associated conditions thereof; Platelet aggregation; Coronary artery disease; Myocardial infarction; Transient ischemic attack; Stenocardia; Apoplexy; Ischemia reperfusion injury; Restenosis; Atrial fibrillation; Angioplasty or coronary bypass operation individuality in or in the individuality suffering from atrial fibrillation clot formed; Atherosclerosis; Congee sample thrombosis; Asthma or its symptom; Diabetes related disorders such as diabetic peripheral neuropathy change, diabetic nephropathy or diabetic retinopathy; Glaucoma or other eye disease with abnormal intraocular pressure; Hypertension; Inflammation; Psoriasis; Arthritic psoriasis; Rheumatoid arthritis; Crohn's disease; Transplant rejection; Multiple sclerosis; Systemic lupus erythematous (SLE); Ulcerative colitis; Ischemia reperfusion injury; Restenosis; Atherosclerosis; Acne; Type 1 diabetes; Diabetes B; Sepsis; And chronic obstructive pulmonary disease (COPD). |
| priorityDate | 2008-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 409.